Personalized Tumor Therapy

Our Services


Scientists at the Regensburg site of Fraunhofer ITEM have extensive expertise in the detection, isolation, and analysis of rare cell populations as well as small amounts of nucleic acids.

Our goal is to advance targeted diagnostics for prevention and therapy for patients with systemic cancers and to improve the preclinical development of new pharmaceutical compounds.

For example, we use Multiomics analysis of single cells and innovative preclinical cell models from patient samples acquired from specific projects for the purpose of generating molecular and functional data. In addition, our GDPR-compliant data management and in-house bioinformatics enable tailored data analysis for developing applications and products for our customers.


Method development

  • Preanalytics & diagnostics
  • Multiomics & single-cell analysis
  • Preclinical cell models & pharmaceutical compound testing
  • Bioinformatics & math. modeling

Preclinical application

  • Customized assays and analyses for the preclinical testing of pharmaceutical compounds and novel immunotherapies
  • Biomarker identification
  • Development/validation of diagnostic tests

Clinical Translation

  • Clinical drug development and biomarker identification
  • Design and implementation of clinical studies at our site in Regensburg and throughout Bavaria (BZKF) 

Highlight: Platform for Ex-Vivo Drug Response Assays (PEDRA)

We have developed a Platform for Ex-Vivo Drug Response Assays (PEDRA) that mirrors the clinical patient situation in vitro by using disease-specific models generated from clinical samples, recruited individually for each project. PEDRA comprises several ex-vivo assays of variable cellular complexity. In combination with state-of-the-art readouts drug safety and efficacy can be assessed for a broad range of anticancer treatments. Because PEDRA preserves the original cellular composition of the organ of interest, it is ideal for testing novel IO therapies incl. CPI and ADC.

© Fraunhofer ITEM, Tonia Bargmann
PEDRA: Disease-specific, patient-derived models for preclinical testing of anti-cancer therapies

Certification of Our “Personalized Tumor Therapy” Division by TÜV SÜD

ITEM is DIN ISO 9001:2015 certified

The “Personalized Tumor Therapy” division at the Regensburg site of Fraunhofer ITEM has been certified by TÜV Süd according to DIN ISO 9001:2015 and thus complies with national international standards in quality management. This is of benefit both to our R&D services and to our customers:

  • Long-term quality assurance
  • Risk minimization
  • Global comparability
  • Continuous optimization of work processes
  • Early detection of potential for improvement
  • Fulfillment of specific customer requirements
  • Greater satisfaction of customers and employees


Christopher Jakobs

Contact Press / Media

Dr. Christopher Jakobs

Business Development for Personalized Tumor Therapy

Phone +49 152 28220636